Tomoya Yokota

Chief

Aichi Cancer Center

Japan

Research Interests

Explore related searches

Professors in Japan

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Tomoya Yokota is the Chief at Shizuoka Cancer Center in Japan. His research focuses on head and neck cancer, exploring topics such as multimodal treatments, the effects of cisplatin dosage, and the implications of radiation therapy on patients. Additionally, he has contributed to studies on lenvatinib rechallenge in metastatic thyroid cancer and the use of pemigatinib in solid tumors. His work is influential in understanding and improving cancer treatments.

Articles (10)

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Collaborators (3)

Naomi Kiyota

Associate Professor

Kobe University Hospital

JAPAN

View details

Koichiro Wasano

Associate professor

Tokai University School of Medicine

JAPAN

View details

Silvia Damian

Fondazione IRCCS Istituto Nazionale dei Tumori

ITALY

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Tomoya Yokota

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

Caution Needed Before Adopting Reduced-Dose Elective Neck Irradiation in Head and Neck Cancer: A Response to UPGRADE-RT

Multimodal treatments for patients with locally advanced synchronous esophageal and head and neck cancer

Publisher Correction: Pemigatinib in previously treated solid tumors with activating FGFR1–FGFR3 alterations: phase 2 FIGHT-207 basket trial

Pemigatinib in previously treated solid tumors with activating FGFR1–FGFR3 alterations: phase 2 FIGHT-207 basket trial

First-line pembrolizumab with or without chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: 5-year follow-up of the Japanese population of KEYNOTE‑048

Impact of relative cisplatin dose to skeletal muscle mass on adverse events in patients with head and neck cancer undergoing chemoradiotherapy

Lenvatinib rechallenge after failure of lenvatinib and sorafenib in metastatic thyroid cancer

Radiation-induced xerostomia and cariogenic dietary habits

Real‐world experience of tropomyosin receptor kinase inhibition with entrectinib in ETV6‐NTRK3 positive metastatic salivary secretory carcinoma: A case series

Real-world experience of tropomyosin receptor kinase inhibition with entrectinib in ETV6-NTRK3 positive metastatic salivary secretory carcinoma: A case series

Collaborators (3)

Naomi Kiyota

Koichiro Wasano

Silvia Damian

Make your next move.